USA-based Light Horse Therapeutics has been established as a new small molecule therapeutics developer, with a $62 million ...

Veralox Therapeutics secures an option to acquire Nudge Therapeutics, adding preclinical cGAS inhibitors to its portfolio. The acquisition complements Veralox’s focus on inflammatory conditions and ...

German biotech CatalYm has appointed Scott Clarke as chief executive (CEO), noting that he brings over two decades of ...

Mountainfield Venture Partners and Keymed Biosciences launch Timberlyne Therapeutics with $180 million in series A funding.

Intellia Therapeutics, a US gene editing company developing CRISPR-based therapies, announced late Thursday its strategic ...

The glaucoma market across the seven major markets is forecast to increase at a compound annual growth rate (CAGR) of 2.1% ...

The FDA approved 50 novel drugs in 2024, including 18 biosimilars, with many targeting rare diseases and offering ...

Numab Therapeutics raises $55 million to advance its multi-specific antibody pipeline targeting inflammation and oncology, ...

USA-based Climb Bio said yesterday it has entered into an exclusive license agreement with Beijing Mabworks Biotech for ...

UCB partners with Ailux Biologics to use XtalPi's AI-driven XtalFold platform for antibody discovery and optimization. The ...

Spanish firm Grifols has submitted a Biologics License Application (BLA) for its new potential fibrinogen treatment to the US ...

Netherlands-based Synaffix, a Lonza company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic ...